Zusammenfassung
Nicht motorische Symptome können bereits vor den motorischen
Symptomen einer Parkinsonerkrankung auftreten. Neben Wirkungsfluktuationen und
Dyskinesien stellen nicht motorische Symptome ein Hauptproblem in der
Behandlung der fortgeschrittenen Parkinsonerkrankung dar. Sie sind von
wesentlicher Bedeutung für die Lebensqualität. Es gibt Hinweise
darauf, dass eine kontinuierliche dopaminerge Stimulation Depression, Schlaf
und autonome Störungen verbessern kann. Medikamentenpumpen mit Apomorphin
subkutan oder Duodopa (L-Dopa / Carbidopagel) intraduodenal haben
sich zur Behandlung von motorischen Wirkungsfluktuationen und Dyskinesien
etabliert. Im Bereich der nicht motorischen Symptome liegen bisher nur wenige
Studien mit kleinen Fallzahlen vor.
Abstract
In Parkinson's disease non-motor symptoms can appear even
before the motor symptoms. Additionally to motor fluctuations and dyskinesias,
the non-motor symptoms constitute one of the main problems when treating
Parkinson's disease. They are also of high relevance for the quality of
life. There are indications that a continuous dopaminergic stimulation can
improve symptoms such as depression, sleep as well as autonomic disturbances.
Treatment with apomorphine infusion subcutaneously or Duodopa
(L-dopa / carbidopa) intraduodenally with portable pump systems
are well-established regarding management of motor fluctuations and
dyskinesias. Regarding effects on non-motor symptoms there are so far only a
few studies with limited number of cases available.
Schlüsselwörter
Parkinson - Pumpe - Apomorphin - Infusion - Non-motor
Keywords
Parkinson - pump - apomorphine - infusion - non-motor
Literatur
- 1
Chaudhuri K R, Healy D, Schapira A HV.
The non motor symptoms of Parkinson's disease. Diagnosis
and management.
Lancet Neurol.
2006;
5
235-245
- 2
Naidu Y, Chaudhuri K R.
Early Parkinson's disease and non motor issues.
J Neurol.
2008;
255
33-38
- 3
Tolosa E et al.
Diagnosis and the premotor phase of Parkinson disease.
Neurology.
2009;
72
(S 02)
S12-S20
- 4 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms
of Parkinson's
disease to healthcare professionals. An international survey using the
NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor
Features in Parkinson's disease and Related Disorders. Park Related
Disorders P0II: 161.. Dresden; October/2008
- 5
Chaudhuri K R, Martinez-Martin P.
Quantitation of non-motor symptoms in Parkinson's
disease.
Eur J Neurol.
2008;
15
2-7
- 6
Chaudhuri K R, Martinez-Martin P, Schapira A HV et al.
An international multicentre pilot study of the first
comprehensive self-completed non-motor symptoms questionnaire for
Parkinson's disease: the NMSQuest study.
Mov Disord.
2006;
21
916-923
- 7
Politis M, Piccini P, Pavese N et al.
Evidence of dopamine dysfunction in the hypothalamus of
patients with Parkinson's disease: an in vivo 11C raclopride study.
Exp Neurol.
2008;
214
112-116
- 8
Storch A, Ebersbach G, Fuchs G et al.
Depression in Parkinson's disease. Part 1: Epidemiology,
signs and symptoms, pathophysiology and diagnosis.
Fortschr Neurol Psychiatr.
2008;
76
715-724
- 9
Remy P, Doder M, Lees A et al.
Depression in Parkinson's disease. Loss of dopamine and
noradrenaline innervations in the limbic system.
Brain.
2005;
128
1314-1322
- 10
Corrigan M H, Denahan A Q, Wright C E et al.
Comparison of pramipexole, fluoxetine, and placebo in
patients with major depression.
Depress Anxiety.
2000;
11
58-65
- 11
Rektorova I, Rektor I, Bares M et al.
Pramipexole and pergolide in the treatment of depression in
Parkinson's disease: a national multicentre prospective randomized
study.
Eur J Neurol.
2003;
10
399-406
- 12
Barone P, Scarzella L, Marconi R et al.
Pramipexole versus sertraline in the treatment of depression
in Parkinson's disease. A national multicenter parallel group randomized
study.
J Neurol.
2006;
253
601-607
- 13
Reichmann H, Brecht M H, Koster J et al.
Pramipexole in routine clinical practice: a prospective
observational trial in Parkinson's disease.
CNS Drugs.
2003;
17
965-973
- 14
Pahwa R, Stacy M A, Factor S A EASE-PD adjunct study
investigators et al, on behalf of the .
Ropinirole 24-hour prolonged release: randomized, controlled
study in advanced Parkinson disease.
Neurology.
2007;
68
1108-1115
- 15
Naidu Y, Logishetty K, Martin A et al.
Efficacy of apomorphine infusion on mood and depression
aspects of non-motor symptoms in advanced Parkinson's disease.
Park Rel Disord.
2009;
15
(S 02)
S130 (P2.149)
- 16
Kulisevsky J, Pascual-Sedano B, Barbanoj M et al.
Acute effects of immediate and controlled release levodopa on
mood in Parkinson's disease: a double blind study.
Mov Disord.
2006;
22
62-67
- 17
Witt K, Daniels C, Reiff J et al.
Neuropsychological and psychiatric changes after deep brain
stimulation for Parkinson's disease: a randomised, multicentre study.
Lancet Neurol.
2008;
7
605-614
- 18 Hagell P, Odin P, Shing M. Apomorphin bei Morbus Parkinson.. Bremen: Uni-Med Verlag;
2005
- 19
Colzi A, Turner K, Lees A J.
Continuous subcutaneous waking day apomorphine in the
long-term treatment of levodopa induced interdose dyskinesias in
Parkinson's disease.
J Neurol Neurosurg Psychiatry.
1998;
64
573-576
- 20
Richard I H, Schiffer R B, Kurlan R.
Anxiety and Parkinson's disease.
J Neuropsychiatry Clin Neurosci.
1996;
8
383-392
- 21
Pluck G C, Brown R G.
Apathy in Parkinson's disease.
J Neurol Neurosurg Psychiatry.
2002;
73
636-642
- 22
Czernecki V, Schupbach M, Yaici S et al.
Apathy following subthalamic stimulation in Parkinson's
disease: a dopamine responsive syndrome.
Mov Disord.
2008;
23
964-969
- 23
Marin R S, Fogel B S, Hawkin J et al.
Apathy: a treatable syndrome.
J Neuropsychiatry Clin Neurosci.
1995;
7
23-30
- 24
Goetz C G, Emre M, Dubois B.
Parkinson's disease dementia: definitions, guidelines,
and research perspectives in diagnosis.
Ann Neurol.
2008;
64
(S 02)
S81-92
- 25
Cools R, Stefanova E, Barker R et al.
Dopaminergic modulation of high-level cognition in
Parkinson's disease: the role of the prefrontal cortex revealed by
PET.
Brain.
2002;
125
584-594
- 26
Mattay V, Tessitore A, Callicott J et al.
Dopaminergic modulation of cortical function in patients with
Parkinson's disease.
Ann Neurol.
2002;
51
156-164
- 27
O'Sullivan S S, Evans A H, Lees A J.
Dopamine dysregulation syndrome: an overview of its
epidemiology, mechanisms and management.
CNS Drugs.
2009;
23
157-170
- 28
Lees A J, Blackburn N A, Campbell V L.
The nighttime problems of Parkinson's disease.
Clin Neuropharmacol.
1988;
11
512-519
- 29
Askenazy J J.
Sleep disturbances in Parkinsonism.
J Neural Transm.
2003;
110
125-150
- 30
Dhawan V, Healy D G, Pal S et al.
Sleep-related problems of Parkinson's disease.
Age Ageing.
2006;
35
220-228
- 31
Stocchi F, Vacca L, Valente M et al.
Sleep disorders in Parkinson's disease.
Adv Neurol.
2001;
86
289-293
- 32 Diederich N, Comella C. Sleep disturbances in Parkinson's disease.. In: Chokroverty S,
Hening W A, Walters A, eds Sleep and Movement Disorders.. Philadelphia: Butterworth,
Heinemann; 2003: 478-488
- 33
Trenkwalder C, Boesch S, Ceballos-Baumann A et al.
Intermittent apomorphine injections as rescue therapy for
advanced Parkinson's disease. Consensus statement.
Nervenarzt.
2008;
79
475-479
- 34
Garcia Ruiz P J.
Nocturnal subcutaneous apomorphine infusion for severe
insomnia in Parkinson's disease.
Mov Disord.
2006;
21
727-728
- 35
Ng K Y, Chase T N, Colburn R W et al.
Dopamine stimulation induced release from central
neurons.
Science.
1971;
1172
487-489
- 36
Rye D B, Jankovic J.
Emerging views of dopamine in modulating
sleep / wake state from an unlikely source: PD.
Neurology.
2002;
58
341-346
- 37
Uchiyama T, Sakakibara R, Hattori T et al.
Short-term eff ect of a single levodopa dose on micturition
disturbance in Parkinson's disease patients with the wearing-off
phenomenon.
Mov Disord.
2003;
18
573-578
- 38
Christmas T, Kempster P, Chapple C et al.
Role of subcutaneous apomorphine in parkinsonian voiding
dysfunction.
Lancet.
1988;
2
1451-1453
- 39 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms
of Parkinson's
disease to healthcare professionals. An international survey using the
NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor
Features in Parkinson's disease and Related Disorders. Park Related
Disorders P0II: 161.. Dresden; October/2008
- 40
O'Sullivan J D, Hughes A J.
Apomorphine induced penile erections in Parkinson's
disease.
Mov Disord.
1998;
13
536-539
- 41
Dula E, Bukofzer S, Perdok R et al.
Double blind crossover comparison of 3 mg apomorphine
SL with placebo and with 4 mg apomorphine SL in male erectile
dysfunction.
Eur Urol.
2001;
39
558-564
- 42
Klos K J, Bower J H, Josephs K A et al.
Pathological hypersexuality predominantly linked to adjuvant
dopamine agonist therapy in Parkinson's disease and multiple system
atrophy.
Park Relat Disord.
2005;
11
381-386
- 43
Edwards L L, Quigley E MM, Harned R K et al.
Defecatory function in Parkinson's disease: response to
apomorphine.
Ann Neurol.
1992;
33
490-493
- 44
Honig H, Antonini A, Martinez-Martin P et al.
Intrajejunal levodopa infusion in Parkinson's disease: a
pilot multicentre study of effects on non-motor symptoms and quality of
life.
Mov Disord.
2009;
24
1468-1474
- 45
Brefel-Courbon C, Payoux P, Thalamas C et al.
Effect of levodopa on pain threshold in Parkinson's
disease: a clinical and positron emission tomography study.
Mov Disord.
2005;
20
1557-1563
- 46
Witjas T, Kaphan E, Azulay J P et al.
Nonmotor fluctuations in Parkinson's disease: frequent
and disabling.
Neurology.
2002;
59
408-413
- 47
Ray Chaudhuri K, Abbott R J, Millac P AH.
Subcutaneous apomorphine for parkinsonian patients with
psychiatric side effects on oral treatment.
J Neurol Neurosurg Psychiatry.
1990;
54
372-373
- 48
Ellis C M et al.
Use of apomorphine therapy in parkinsonian patients with
neuropsychiatric complications to oral therapy.
Parkinsonism and Related Disorders.
1997;
3
103-107
- 49
van Laar T, Postma A G, Drent M.
Continuous subcutaneous infusion of apomorphine can be used
safely in patients with Parkinson's disease and pre-existing visual
hallucinations.
Park Relat Disord.
2010;
16
71-72
- 50 Martinez-Martin P, Todorova A, Henriksen T et al. The motor and non motor efficacy
of subcutaneous apomrophine
infusion in chronic advanced PD compared to Parkinson's patients on
conventional therapy. A „real life” study.
Mov Disord 2010.
Abstract In Press. To be Presented to Movement Disorders Congress. Buenos Aires;
June 2010
Prof. Dr. med. Per Odin
Abt. Neurologie, Klinikum-Bremerhaven
Postbrookstr. 103
27574 Bremerhaven
Email: Per.odin@klinikum-bremerhaven.de
